Latest Aura Biosciences News & Updates
See the latest news and media coverage for Aura Biosciences. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing targeted therapies for solid tumors
aurabiosciences.com- Headquarters
- Boston, United States
- Founded year
- 2009
- Company type
- Public company
- Number of employees
- 125–200
Last updated
Latest news about Aura Biosciences
In short: Aura Biosciences appointed Natalie Holles as CEO, secured $299 million in financing, and advanced its Phase 3 CoMpass trial for ocular melanoma.
Company announcements
-
Aura Biosciences reports Q1 2026 financial results and business highlights
Phase 3 CoMpass trial nearing enrollment completion; topline data expected in 2H 2027. New CEO appointed, and $299M equity financing strengthened cash position.
-
Aura Biosciences announces closing of $299 million public offering
The offering includes full exercise of underwriters' option, selling 46 million shares and pre-funded warrants at $6.00 per share.
-
Aura Biosciences announces $260 million public offering pricing
The offering includes 39,591,000 common stock shares at $6.00 each and pre-funded warrants. Proceeds will fund clinical programs and repurchase shares from Matrix Capital. Expected to close May 5, 2026.
-
Aura Biosciences announces proposed public offering
It is offering common stock and pre-funded warrants; underwriters have a 30-day option to purchase up to 15% additional shares.
Media coverage
-
Aura Biosciences CEO Elisabet de los Pinos sells $98,787 in stock
InvestingPro Insights As Aura Biosciences' CEO Elisabet de los Pinos executed a stock sale for tax purposes, investors might be interested in additional financial insights...
-
Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights
Phase 3 CoMpass trial advancing toward enrollment completion, supporting 2H 2027 topline dataNatalie Holles appointed Chief Executive Officer and...
-
Aura Biosciences Announces Stock Repurchase Agreement with Shareholder
Detailed price information for Aura Biosciences Inc (AURA-Q) from The Globe and Mail including charting and trades.
-
Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion
Detailed price information for Aura Biosciences Inc (AURA-Q) from The Globe and Mail including charting and trades.
Track Aura Biosciences and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Trending companies
Discover what's making headlines across other trending companies.